Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211991 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Consistency of StaphVAX Manufacturing Lots
A Phase 3 study, sponsored by Nabi Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 354
- Enrollment target
NCT00211991: Completed Phase 3 study, sponsored by Nabi Biopharmaceuticals.
NCT00211991 is a Phase 3 study that has completed, run by Nabi Biopharmaceuticals. The registered enrollment target is 354 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00211991, a Phase 3 study, has completed, sponsored by Nabi Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 354 participants
- Enrollment target
Study Summary
This study answers a U.S. Food and Drug Administration requirement for evaluation in people of the consistency of manufacturing of a vaccine. Subjects are randomized to one of three lots of vaccine. The antibodies in the blood measure the immunogenicity of each lot of vaccine, and typical vaccine safety information is also collected.
Interventions
- BIOLOGICAL S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2005-04 |
| Est. Completion | 2005-07 |
| Phase | Phase 3 |
What the finished NCT00211991 record still lists
NCT00211991 is an interventional study that assigns participants to a tested intervention. The registered 354 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (54% lower).
The record links to 0 conditions, and to 1 intervention - of which S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate is the first listed.
NCT00211991 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00211991 about?
NCT00211991 is a clinical study titled "Evaluation of Consistency of StaphVAX Manufacturing Lots". This study answers a U.S. Food and Drug Administration requirement for evaluation in people of the consistency of manufacturing of a vaccine. Subjects are randomized to one of three lots of vaccine. The antibodies in the blood measure the immunogenicity of each lot of vaccine, and typical vaccine sa...
What is the current status of trial NCT00211991?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 354 participants. The study started on 2005-04. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00211991?
The interventions under investigation include: S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate (BIOLOGICAL).
Who is sponsoring clinical trial NCT00211991?
This trial is sponsored by Nabi Biopharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00211991's enrollment target sits among peer trials
354 1026th of 2000 higher than 973 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT02610413 · 354 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
- NCT05729256 · 354 participants · NA
Alcohol and "Heat of the Moment" Sexual Decision Making
- NCT06507618 · 354 participants · Phase 3
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia